STANDARD BIOTOOLS INC. 8-K

What Happened
Standard BioTools Inc. (LAB) filed an 8-K reporting that on May 21, 2026 the Board approved a 2026 Change of Control and Severance Plan (the “2026 Severance Plan,” term through Aug 4, 2028). On May 27, 2026 CFO Alex Kim and Chief Business Officer Sean Mackay signed participation agreements under the 2026 plan. Separately, on May 22, 2026 CEO Michael Egholm, Ph.D., entered into a participation agreement under the company’s amended 2023 Change of Control and Severance Plan (the “2023 Severance Plan”); Dr. Egholm is the sole participant under the 2023 plan.

Key Details

• 2026 Severance Plan term runs until Aug 4, 2028; it replaces prior 2024 plan for participating non‑CEO executives.
• Non‑CEO standard severance (outside a Change of Control Period): 100% of base salary paid over 12 months, pro‑rated target bonus, up to 12 months of health‑coverage reimbursement, and (if termination occurs on or before Aug 27, 2026) 100% acceleration of unvested equity (performance awards assumed at target).
• Non‑CEO in a Change of Control Period: lump sum equal to 150% of (base salary + greater of target bonus or 3‑year bonus average), pro‑rated target bonus, up to 18 months health coverage, and 100% equity vesting acceleration (performance assumed at target).
• CEO (2023 Plan) outside Change of Control: 200% of base salary paid over 24 months, up to 12 months health coverage. CEO in a Change of Control Period: lump sum equal to 250% of (base salary + greater of target bonus or 3‑year bonus average), pro‑rated target bonus, up to 30 months health coverage, and 100% equity vesting acceleration (performance assumed at target).

Why It Matters
These plans formalize severance and change‑of‑control protections for senior leadership, strengthening executive retention and providing clarity on potential post‑termination obligations. For investors, the provisions could increase potential cash outflows and accelerate equity vesting in the event of terminations or a change of control, which may affect near‑term cash needs and equity dilution in certain scenarios. The filing does not indicate any immediate cash payment.